Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer - Report - MDSpire
Advertisement
Case Report: early regression and bladder-intact survival after limited-course immunotherapy-based systemic therapy in two patients with clinically staged bulky muscle-invasive bladder cancer
Clinical Report: Early Tumor Regression and Bladder Preservation Following Short-Term Immunotherapy
Overview
This report presents two cases of early tumor regression in patients with bulky muscle-invasive bladder cancer (MIBC) following limited-course immunotherapy. Both patients achieved bladder-intact survival for approximately three years without immediate radical cystectomy.
Background
Muscle-invasive bladder cancer (MIBC) poses a significant risk of progression and mortality, with radical cystectomy being the standard treatment. Recent advances in immunotherapy have prompted investigations into bladder preservation strategies, although these approaches require careful patient selection and monitoring. Understanding early response kinetics in immunotherapy may inform future treatment pathways.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
Both patients demonstrated marked tumor regression after two cycles of immunotherapy-based systemic therapy.
Case 1 received tislelizumab plus platinum-based chemotherapy, while Case 2 received toripalimab plus disitamab vedotin.
Post-treatment assessments in Case 2 showed no definite residual malignancy.
Both patients declined recommended radical cystectomy despite the observed regression.
No clinically detectable recurrence was identified at approximately three years of follow-up.
Clinical Implications
These cases suggest that early response to immunotherapy may identify exceptional responders who could be candidates for bladder preservation strategies. However, the findings do not support the routine omission of radical cystectomy.
Conclusion
The documented early regression in these cases highlights the potential for immunotherapy in managing bulky MIBC, warranting further investigation into response-adapted treatment strategies.
